...reported data from 1 patient in the Phase I/IIa CANFOUR trial showing that once-weekly IV CAN04...
...adverse events. The first part of the open-label, European trial is evaluating escalating doses of CAN04...
...pancreatic cancer, colorectal cancer or triple-negative breast cancer (TNBC), and the second part will evaluate CAN04...

...of its lead program from cancers of the blood to solid tumors. After finding its anti-IL-1RAP mAb...
...planned indication of chronic myelogenous leukemia (CML). The Lund University spinout built its lead compound, CAN04...
...need is lower, and the indication didn't fully capitalize on the immune defense properties of CAN04...

...Cantargia said its anti-IL-1RAP mAb significantly inhibited tumor growth in an animal model of malignant melanoma. Details...
...plans to identify a lead compound by year end. Cantargia AB , Lund, Sweden Product: Anti-IL-1RAP mAb...

...much lower concentration, so the company hopes there will not be enough to sequester an anti-IL-1RAP mAb...